A concise overview of the essential Health Technology Assessment domains every drug developer must address.

Use this checklist to design and execute development programs that directly address payer needs across all ten HTA domains. Tick each box as you confirm implementation – ensuring your asset is primed for a smooth P&R journey.

The 10 Essential HTA Domains

Clinical Effectiveness

Broaden inclusion criteria (when scientifically justifiable) and document how your trial’s population boosts generalizability and minimizes payer uncertainty.

Health-Related Quality of Life

Embed generic QoL instruments (EQ-5D or SF-36) alongside disease-specific scales to demonstrate both nuanced patient impact and broad utility for economic modeling.

Cost-Effectiveness

Source real-world cost data and document model assumptions clearly – demonstrate the reliability and relevance of your economic inputs to avert hidden-cost concerns.

Safety & Tolerability

Invest in proactive risk-mitigation: design trials with clear monitoring plans, adopt companion diagnostics for high-risk subgroups, and publish safety narratives early.

Comparator Selection

If multiple SOCs exist, include network meta-analyses or multi-arm trials – explain clearly how each comparator was chosen and why it reflects real practice.

Patient Population

Design trials with broad eligibility where scientifically justified, and prespecify subgroup endpoints; document the rationale so payers understand your generalizability plan.

Care Pathway Integration

Optimize formulation and dosing for ease of use, and pilot integration studies in representative centers to iron out workflow challenges before submission.

Resource Use & Budget Impact

Minimize implementation costs: optimize delivery formats, streamline training needs, and pilot in representative centers to model real-world affordability.

Evidence Quality & Robustness

Publish interim and final results promptly; supplement your RCTs with real-world studies or meta-analyses to confirm reproducibility and completeness.

Uncertainty & Sensitivity

Build in subgroup and system-impact studies early – show how your treatment addresses unmet needs or reduces caregiver burden, and preempt potential societal objections.

See Your Edge

Tick every box to future-proof your development program, reduce payer pushback and accelerate market access.

Do you know how your asset measures up with the competition in the MARA Rating?

Visit mararating.com or send us a line at sales@mararating.com.

#DrugDevelopment #MarketAccess #HTA #EvidenceStrategy #MARARating #MarketAccessScore